Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
RESMED, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 164 USD | +1.89% | +3.24% | -21.20% | |
| Nov. 30 | Resmed Insider Sold Shares Worth $457,860, According to a Recent SEC Filing | MT |
| Nov. 17 | Resmed Insider Sold Shares Worth $863,281, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 4.62B | Sales 2025 * | 4.92B | Capitalization | 24.12B |
|---|---|---|---|---|---|
| Net income 2024 * | 992M | Net income 2025 * | 1.13B | EV / Sales 2024 * | 5,34x |
| Net Debt 2024 * | 556M | Net cash position 2025 * | 532M | EV / Sales 2025 * | 4,79x |
| P/E ratio 2024 * | 24,6x | P/E ratio 2025 * | 22,1x | Employees | 10,140 |
| Yield 2024 * | 1,19% | Yield 2025 * | 1,27% | Free-Float | 77.21% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | +1.89% | ||
| 1 week | +3.24% | ||
| Current month | +3.98% | ||
| 1 month | +6.58% | ||
| 3 months | +6.96% | ||
| 6 months | -26.12% | ||
| Current year | -21.20% |
1 week
156.39
165.39
1 month
140.81165.39
Current year
132.24243.52
1 year
132.24243.52
3 years
132.24301.34
5 years
90.64301.34
10 years
41.52301.34
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Farrell
FOU | Founder | 80 | 1989 |
Mick Farrell
CEO | Chief Executive Officer | 50 | 2000 |
Rob Douglas
PSD | President | 63 | 2000 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 50 | 2000 |
Ron Taylor
BRD | Director/Board Member | 75 | 2004 |
Peter Farrell
FOU | Founder | 80 | 1989 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.52% | 1 M€ | -10.24% | ||
| 6.52% | 1 M€ | -11.72% | ||
| 3.58% | 4 M€ | -7.43% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 164 | +1.89% | 1,116,154 |
| 23-12-05 | 160.95 | -0.36% | 796,356 |
| 23-12-04 | 161.53 | +1.18% | 1,103,146 |
| 23-12-01 | 159.64 | +1.21% | 704,931 |
| 23-11-30 | 157.73 | -0.71% | 1,641,217 |
Delayed Quote Nyse, December 06, 2023 at 04:00 pm EST
More quotes
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
2024-01-24
- Q2 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
164USD
Average target price
183.55USD
Spread / Average Target
+11.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.20% | 24 121 M $ | |
| -10.33% | 191 B $ | |
| -16.83% | 163 B $ | |
| +16.92% | 109 B $ | |
| +18.48% | 80 310 M $ | |
| +12.56% | 63 346 M $ | |
| -10.80% | 47 620 M $ | |
| -6.86% | 42 146 M $ | |
| -13.86% | 37 658 M $ | |
| +16.56% | 30 979 M $ |
